Skip to main content

Table 2 Patient utility values for health states

From: Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US

 

Utility value (BSC arm)

Source

Utility value (nusinersen arm)

Source

Permanent ventilation

0.19

Thomson et al., 2017 [18]

0.19

Thomson et al., 2017 [18]

Not sitting

0.19

0.29

Assumption

Sitting

0.60

Tappenden et al., 2018 [19]

0.65

Assumption

Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us